English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim: Estimate the cost and economics of the purchase of medicines provided through lawsuit considering the acquisition of branded medicines, generic and similar equivalent. Methods: The descriptive and analytical study of deferred lawsuits (n = 186) for access to medicines demanded in the Antonio Prado – RS, between the years 2004 to 2015, investigated the cost of the medicines for the full compliance of the shares considering three scenarios: A the acquisition of brand name medicines; B the acquisition of generic and C acquisition of smaller value considering brand name drug, generic equivalent or similar. The financial impact of this difference was estimated as the annual cost of the acquisition of Pharmaceutical Services Basic Component (CBAF) of this municipality. Results: The accumulated amount required for full compliance with the active lawsuits between the years 2004 to 2015 would be R $ 6,592,936.58 for scenario A, of R $ 5,573,571.19 for the scenario B and R $ 5,357,309.82 for scenario C. The percentage saving compared to scenario A was 13.44% for the acquisition of generic drugs (scenario B) and 17.94% for the acquisition of lower drug (C scenario). This difference in cost of the branded drugs ordered through judicial processes is over than

Qual é o custo da prescrição pelo nome de marca na judicialização do acesso aos medicamentos?